Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma

Last updated: July 3, 2024
Sponsor: University Hospital Tuebingen
Overall Status: Completed

Phase

N/A

Condition

Cervical Intraepithelial Neoplasia

Neoplasms

Genitourinary Cancer

Treatment

Non-invasive physical plasma

Clinical Study ID

NCT04753073
ZGynO_CIN_III
  • Ages > 18
  • Female

Study Summary

The aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of NIPP against CIN III lesions.

  • The aim of this project is to evaluate the potential of a previous NIPP treatment to significantly reduce the invasiveness of the LEEP excision.

  • Another aim of this study is to investigate cellular / molecular effects of NIPP following the in-vivo treatment of the cervix using molecular biological methods. For this purpose, tissue treated with plasma is taken after defined periods of time by mini biopsy and examined using molecular biological, histological and microscopic methods.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Histologically confirmed CIN III

  • Clearly visible transformation zone of the portio and margins of the lesionsaccording to T1 / T2

  • signed written consent

Exclusion

Exclusion Criteria:

  • Not fully visible transformation zone

  • Indication of an invasive disease

  • Serious cardiovascular diseases

  • Patients who only want to undergo a LEEP excision

Study Design

Total Participants: 38
Treatment Group(s): 1
Primary Treatment: Non-invasive physical plasma
Phase:
Study Start date:
February 01, 2021
Estimated Completion Date:
June 30, 2024

Study Description

Cervical intraepithelial neoplasms (CIN), classified into severity levels CIN I to III, can be precursors to cervical cancer (CC), the world's third most common cancer in women (270,000 deaths / year), which radical therapies are often associated with lifelong severe physical and emotional stress. Cross-sectional studies found a prevalence for CIN of 62 per 1,000 women and incidences of 1.2 (CIN I), 0.8 (CIN II) and 0.7 (CIN III) per 1,000 women per year (highest incidence of CIN between 20 and 24 years) age). The standard therapy for the treatment of CIN III by LEEP excision is associated with an increase in mortality of 17%. CIN III, in particular, is associated with a significant decline in quality of life, psychological well-being and sexual health, although on average only about 12% of CIN III lesions progress to invasive CC. The resulting over-treatment (in around 8-9 out of 10 patients) with invasive procedures is a serious problem for affected women, health care providers and the health economy.

The NIPP treatment is a tissue-sparing, pain-free, easy to carry out and outpatient treatment method without anesthesia and hospitalization. A non-randomized, one-arm feasibility study at the Department of Women's Health (649 / 2017BO1) already showed the effectiveness of a NIPP treatment.

Clinical implications for CIN III:

  • A previous NIPP treatment should significantly reduce the invasiveness of the LEEP excision.

  • If the oncological safety of NIPP treatment is comparable (histological complete remission of CIN III), NIPP is to be established as a safe alternative to LEEP excision in the future.

Connect with a study center

  • University Hospital Tuebingen, Department of Women's Health

    Tuebingen, 72076
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.